Ovarian function suppression: To what extent is it necessary for premenopausal patients with operable hormone-sensitive breast cancer?
The use of tamoxifen is conventional adjuvant hormone therapy in premenopausal patients with receptor-positive breast cancer. Clinical trials demonstrating the benefits of ovarian function suppression as adjuvant treatment had an ambiguous interpretation. There is no scientific evidence favoring the...
Main Author: | P. V. Koposov |
---|---|
Format: | Article |
Language: | Russian |
Published: |
ABV-press
2015-09-01
|
Series: | Опухоли женской репродуктивной системы |
Subjects: | |
Online Access: | https://ojrs.abvpress.ru/ojrs/article/view/446 |
Similar Items
-
Research progress on the effect of chemotherapy drugs on ovarian function in breast cancer
by: HUANG Miaojun, et al.
Published: (2024-03-01) -
THE ROLE OF OVARIAN SUPPRESSION IN THE TREATMENT OF EARLY-STAGE HORMONE-SENSITIVE BREAST CANCER
by: I. A. Koroleva, et al.
Published: (2018-08-01) -
Individual approach to choosing an appropriate regimen of adjuvant hormone therapy in patients with early-stage breast cancer
by: E. M. Slonimskaya, et al.
Published: (2018-10-01) -
Is the extension of adjuvant hormone therapy for breast cancer justified?
by: V. F. Semiglazov, et al.
Published: (2020-07-01) -
An Overview of Long-Acting GnRH Agonists in Premenopausal Breast Cancer Patients: Survivorship Challenges and Management
by: Nathalie LeVasseur, et al.
Published: (2024-07-01)